K-877 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses K-877 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- K-877-ER
- 2
Studies by the year they started
5 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Tofogliflozin (2) · Peptidoglycan Complex of Spirulina K-001 (1) · Moxifloxacin (1)
Studies
Open first, then newest update. How each study uses K-877 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisCompletedPhase 2Kowa Research Institute, Inc.NCT05327127Written as K-877-ER
- Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IRCompletedPhase 2Kowa Research Institute, Inc.NCT04447820Written as K-877-ER (Dose A)
- Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452CompletedPhase 1Kowa Research Institute, Inc.NCT05722262Written as K-877-ER
- Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.CompletedPhase 1Kowa Research Institute, Inc.NCT03702673Written as K-877 CR Tablet A
- A Thorough Corrected QT Interval TrialCompletedPhase 1Kowa Research Institute, Inc.NCT02073084Written as K-877 Low Dose